TScan Therapeutics Named the Highest-Placed Midsize Biotechnology Company in The Top Places to Work for 2022 by The Boston Globe

December 1, 2022

https://www.globenewswire.com/news-release/2022/12/01/2565881/0/en/TScan-Therapeutics-Named-the-Highest-Placed-Midsize-Biotechnology-Company-in-The-Top-Places-to-Work-for-2022-by-The-Boston-Globe.html

WALTHAM, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq:TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced it has been named one of the Top Places to Work in Massachusetts in the 15th annual employee-based survey project from The Boston Globe. The Top Places to Work 2022 was published online at Globe.com/TopPlaces and will appear in the Globe Magazine on Sunday, December 4, 2022. TScan ranks as the top midsize biotechnology company, and 8th out of the top fifty midsize companies overall in the Top Places to Work in Massachusetts in the 15th annual employee-based survey project.

Read more at globenewswire.com

Related news for (TCRX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.